Experiencia local con natalizumab en pacientes con enfermedad de Crohn refractaria a anti-TNF: Casos clínicos

Fluxá, Daniela; Ibáñez, Patricio; Flores, Lilian; Figueroa, Carmen; Lubascher, Jaime; Kronberg, Udo; Simian, Daniela; Pizarro, Gonzalo; Toche, Paola; Quera, Rodrigo

doi:10.4067/s0034-98872017000400015

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The α4 subunit of the integrins α4β1 and α4β7 expressed by leukocytes binds to vascular cell adhesion molecule 1 (VCAM-1) and MAdCAM-1. It blocks leukocyte adhesion and migration from blood vessels into inflamed tissue [27,28]; -Integrin inhibitor α4β7: Vedolizumab is a humanized monoclonal antibody directed against the intestinal integrin α4β7, which is expressed on T and natural killer (NK) cells and immune cell subsets. The binding of this integrin to MAdCAM-1 allows lymphocytes to enter inflamed tissue.…”

Section: Therapeutic Possibilitiesmentioning

confidence: 99%

The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate–Severe Crohn’s Disease: A Systematic Review

Avedillo-Salas,

Corral-Cativiela,

Fanlo-Villacampa

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Conventional therapy is the most commonly used treatment for Crohn’s disease (CD), but it does not always achieve disease control, which is why the use of biologic drugs is increasing. The aim of this study was to analyze the efficacy and safety of biologic drugs in adult patients diagnosed with moderate–severe CD. An intensive search was performed in PubMed, Web of Science and Medline to collect phase 2 or 3 clinical trials published between 2018 and 2023 that were randomized, placebo-controlled and double-blind trials analyzing the efficacy and safety of biologic drugs in adult patients diagnosed with CD. This systematic review was conducted according to the PRISMA statement. Thirteen clinical trials evaluating eight biologic drugs were included. Upadacitinib, vedolizumab, adalimumab, guselkumab, mirikizumab, ustekinumab and risankizumab showed statistically significant efficacy across different clinical, endoscopic, histological, genetic, biomarker or quality-of-life parameters. However, PF-00547659 only showed statistically significant results for the CDAI-70 at week 12. In terms of safety, the incidence and severity of adverse effects were analyzed, with all drugs being well tolerated and presenting a good safety profile since most adverse effects were mild. Biologic drugs can be considered an effective and safe option for the treatment of moderate–severe CD in adult patients with an inadequate response or intolerance to conventional therapy.

show abstract

Section: Therapeutic Possibilitiesmentioning

confidence: 99%